Molecular biology and the diagnosis and treatment of liver diseases

Screening and identification of target genes differentially expressed in HepG2 cells treated with arsenic trioxide by suppression subtractive hybridization technique

AIM: To clone and identify human genes differentially expressed in human hepatocarcinoma HepG2 cells treated with arsenic trioxide by constructing a subtractive cDNA library with suppression subtractive hybridization (SSH) technique, and to elucidate the molecular mechanism of arsenic trioxide in the regulation of liver cells.

METHODS: The mRNA was isolated from HepG2 cells treated with arsenic trioxide and PBS, respectively, and then cDNA was synthesized. After digestion of restriction enzyme RsaI, small sizes cDNA were obtained. Then the tester cDNA was subdivided into two portions and each was ligated with a different cDNA adaptor. After the tester cDNA was hybridized with driver cDNA (twice) and underwent nested polymerase chain reaction (PCR) (twice), the DNA fragment was subcloned into T/A plasmid vectors to establish the subtractive cDNA library. Amplification of the library was performed in E. coli strain JM109. The amplified cDNA was sequenced and analyzed in GenBank with BLAST search after colony PCR.

RESULTS: The subtractive cDNA library of genes differentially expressed in HepG2 cells treated with arsenic trioxide was constructed successfully. The amplified library contained 109 positive clones. Colony PCR showed that these clones all contained 200-1 000 bp inserts. Thirty-six clones were analyzed by sequencing and bioinformatics. The results showed there were 15 coding sequences with known function and 6 novel ones with unknown function.

CONCLUSION: A subtractive cDNA library of genes differentially expressed in HepG2 cells treated with arsenic trioxide was constructed successfully using SSH technique.

Expression and immunoactivity of chimeric particulate antigens of receptor binding site-core antigen of hepatitis B virus

AIM: To improve the immunogenicity of receptor binding site of hepatitis B virus (HBV) on preS1 antigen using HBV core antigen as an immuno-carrier.

METHODS: One to 6 tandem copies of HBV preS1 (21-47) fragment were inserted into HBcAg at the sites of aa 78 and 82, and expressed in E.coli. ELISA, Western blot and animal immunization were used to analyze the antigenicity and immmunogenicity of purified particulate antigens. The ability to capture HBV by antibodies elicited by chimeric particles was detected with immuno-capture PCR.

RESULTS: Recombinant antigens CI, CII, CIII carrying 1-3 copies of HBV preS1 (21-47) individually could form virus-like particles (VLPs), similar to HBcAg in morphology. But recombinant antigens carrying 4-6 copies of HBV preS1 (21-47) were poorly expressed in E.coli. Chimeric antigens were lacking of immunoreactivity with anti-HBc monoclonal antibodies (McAbs), but still reserved good immunoreactivity with anti-HBe McAbs. CI, CII, CIII could strongly react with anti-preS1 McAb, suggesting that preS1 (21-47) fragment was well exposed on the surface of chimeric VLPs. Three chimeric VLP antigens (CI, CII and CIII) could stimulate mice to produce high-level antibody responses, and their immunogenicity was stronger than non-particulate antigen 21-47*6, containing 6 copies of preS1 (21-47). Mouse antibodies to CI, CII and CIII were able to capture HBV virions in immuno-capture PCR assay in vitro.

CONCLUSION: Chimeric particulate antigens of receptor binding site-core antigen of HBV can elicit strong antibody responses to preS1. They have a potential to be developed into prophylactic or therapeutic vaccines against HBV infection.

The nuclear pore complex protein Tpr is a common autoantigen in sera that demonstrate nuclear envelope staining by indirect immunofluorescence

We studied the autoantigen targets of 75 human sera that had antibodies to the nuclear envelope (NE) as identified by indirect immunofluorescence (IIF) on HEp-2 cells. Several different IIF staining patterns could be identified when antibodies to different components of the nuclear membrane (NM) and nuclear pore complexes (NuPC) were identified: a smooth membrane pattern characteristic of antibodies to nuclear lamins, a punctate pattern typical of antibodies to the nuclear pore complex and more complex patterns that included antibodies to nuclear and cytoplasmic organelles. Western immunoblotting of isolated nuclear and NE proteins and immunoprecipitation of radiolabelled recombinant proteins prepared by using the full-length cDNAs of the Translocated promoter region (Tpr), gp210 and p62 were used to identify specific autoantibody targets. Fifty-two of the 75 (70%) sera bound to Tpr, 25 (33%) bound to lamins A, B or C, 15 (20%) reacted with gp210 and none reacted with p62. Sixteen (21%) did not react with any of the NE components tested in our assays. The clinical features of 37 patients with anti-NE showed that there were 34 females and three males with an age range of 16-88 years (mean 59 years). The most frequent clinical diagnosis (9/37 = 24%) was autoimmune liver disease (ALD; two with primary biliary cirrhosis), followed by seven (19%) with systemic lupus erythematosus (SLE), four (11%) with a motor and/or sensory neuropathy, three (8%) with anti-phospholipid syndrome (APS), two with systemic sclerosis (SSc), two with Sjögren's syndrome (SjS), and others with a variety of diagnoses. This report indicates that Tpr, a component of the NuPC, is a common target of human autoantibodies that react with the NE.

Autoantigens of the nuclear pore complex

The nuclear envelope (NE) is one of many intracellular targets of the autoimmune response in patients with autoimmune liver disease, systemic lupus erythematosus, and related conditions. In eukaryotic organisms the NE consists of five interconnected regions: an outer nuclear membrane (ONM) that is continuous with the endoplasmic reticulum, an intermembrane or perinuclear space, an inner nuclear membrane (INM) with a unique set of integral membrane proteins, the underlying nuclear lamina, and the pore domains that are regions where the ONM and INM come together. The pore domains are sites of regulated continuity between the cytoplasm and nucleus that are occupied by supramolecular structures, termed nuclear pore complexes (NPCs). Human autoantibodies identified to date bind to specific components in three of the five NE compartments. Autoantigen targets include the lamins A, B, and C of the nuclear lamina, gp210, p62 complex proteins, Nup153, and Tpr within the NPC, and LBR, MAN1, LAP1, and LAP2 that are integral proteins of the INM. Autoantibodies to these NE targets have been shown to be correlated with various autoimmune diseases such as primary biliary cirrhosis, other autoimmune liver diseases and systemic rheumatic diseases. Now that the proteome of the NE is more clearly defined, other autoantibodies to components in this cell compartment are likely to be defined.

N/A

N/A

Anti-hepatoma effect and its mechanism of arsenic trioxide on experimental liver cancer

AIM: To study the synergistic anti-hepatoma efficacy of arsenic trioxide (As₂O₃) and matrine in the treatment of experimental rat hepatocellular carcinoma (HCC) induced by 2-acetamidofluorene (2-FAA) and to elucidate the possible mechanisms.

METHODS: SD rats (2 mo old) were fed with 2-FAA for 8 weeks to induce HCC, then treated with As₂O₃ and matrine. On day 29, we weighed the liver and counted liver tumors. The histological changes of the liver were observed under microscope, and the cellular dynamic parameters were studied by flow cytometry. Immunohistochemistry (two-step method) was used to observe the expression of vascular endothelial growth factor (VEGF) and to show micro-vessel density (MVD) on consecutive sections. The pathological parameters were analyzed at the same time. The levels of serum AST, ALT, TBi and DBi were also investigated.

RESULTS: The number of liver tumors decreased significantly in groups treated with As₂O₃, especially in middle-dose (1 mg/kg) group (P < 0.01). Treatment with As₂O₃ caused HCC cell death via apoptosis. Necrosis was seldomly found and apoptosis was common when the dose was appropriate (1 mg/kg). Proliferation index (PI) decreased sharply in middle-dose (1 mg/kg) group (P < 0.01), but not in another (0.2 mg/kg) group (P > 0.05). However, S phase fraction (SPF) decreasd dramatically in the two groups, it reached the top only when the dose (1 mg/kg) was appropriciate (P < 0.01), and it was obviously accompanied with accumulation of cells in G₀/G₁ (G₀/G₁ restriction). The inhibitory effects of As₂O₃ on HCC cells were not significantly enhanced by matrine. Comparied with single treatment with As₂O₃ 1 mg/kg or 0.2 mg/kg, G₀/G₁ phase cells in the group of combination treatment with As₂O₃ 1 mg/kg or 0.2 mg/kg and matrine 4.2 g/kg did not increased, and apoptostic cells with fractional DNA content did not increased either. The expression of VEGF and MVD was significantly lower in middle-dose (1 mg/kg) group (P < 0.01) than that in normal saline group. In comparison with normal saline group, administration of As₂O₃ or/and matrine lowered the levels of AST in serum (P < 0.05), but had no effect on the amount of serum AST, TBi and DBi (P > 0.05).

CONCLUSION: Arsenic trioxide inhibits growth of experimental hepatocellular carcinoma in rats induced by 2-acetamidofluorene, but As₂O₃ has no obvious effect on the normal hepatic cells. The mechanisms may involved in decreasing cell mitosis, accumulating cells in G₀/G₁ phrase, inducing apoptosis of tumer cells, and having inhibitory effects on the angiogeninase through inhibiting vascular endothelial growth factor. Matrine with As₂O₃ has not significantly synergistic anti-hepatoma effects.

Expression of PCNA and nm23-H1/NDPK in Hepatocellular Carcinoma following transcatheter arterial chemoembolization therapy

AIM

To study the effect of transcatheter arterial Chemoem-bolization (TACE) on the proliferation and metastasis of the hepatocellular carcinoma (HCC).

METHODS

Seventy-two patients with inoperable huge HCC administered from 1992 to 2000 were treated with TACE initially, and then operated following the shrinkage of the tumor. During same periods of treatment, there were comparable 487 HCC patients who were not treated with TACE, of which 32 pairs of patients who met with the criteria were selected for this study based on the 10 items screening criteria including gender, age, history of the disease, BUS examination. Expression of proliferating of cell nuclear antigen (PCNA) and nm23-H1 were studied by immunohistochemistry.

RESULTS

PCNA label index (PCNA LI) of HCC following TACE was elevated. The distribution of PCNA LI in the range ≤25%, 26-50%, 51-75% and ＞75% is 75%, 14.3%, 10.7% and 0% in control group, and 35.7%, 21.4%, 28.6% and 14.3%, in TACE group (P<0.01, n = 28), respectively. The expression of nm23-H1 gene exists in both cytoplasm and nuclear with no significant difference between treatment and control group.

CONCLUSION

The proliferative activity of residual tumor of HCC following TACE causes the elevation of PCNA LI implying the poor prognosis of long-term effect of TACE, and therefore, it is necessary to perform two stage-resection after TACE of HCC.

A mutation specific polymerase chain reaction for detecting hepatitis B virus genome mutations at nt551

AIM: The hepatitis B surface antigen (HBsAg) is considered to be one of the best markers for the diagnosis of acute and chronic HBV infection. But in some patients, this antigen cannot be detected by routine serological assays despite the presence of virus. One of the most important explanations for the lack of detectable HBsAg is that mutations which occur within the “a” determinant of HBV S gene can alter expression of HBsAg and lead to changes of antigenicity and immunogenicity of HBsAg accordingly. As a result, these mutants cannot be detected by diagnosis assays. Thus, it is essential to find out specific and sensitive methods to test the new mutants and further investigate their distribution. This study is to establish a method to investigate the distribution of the HBsAg mutant at nt551.

METHODS: A mutation specific polymerase chain reaction (msPCR) was established for amplifying HBV DNA with a mutation at nt551. Four sets of primer pairs, P551A-PPS, P551G-PPS, P551C-PPS and P551T-PPS, with the same sequences except for one base at 3’ terminus were designed and synthesized according to the known HBV genome sequences and the popular HBV subtypes, adr and adw, in China. At the basis of regular PCR method, we explored the specific conditions for amplifying HBV DNAs with a mutation at nt551 by regulating annealing temperature and the concentration of these primers. 126 serum samples from patients of hepatitis B were collected, among which 16 were positive for HBV S DNA in the nested PCR amplification. These 16 HBV S DNAs were detected by using the msPCR method.

RESULTS: When the annealing temperature was raised to 71 °C, nt551A and nt551G were amplified specifically by P551A-PPS and P551G-PPS; At 72 °C and 5 pmole of the primers (each) in reaction of 25 μl volume, nt551C and nt551T were amplified specifically by P551C-PPS and P551T-PPS. 16 of HBV S gene fragments were characterized by using this method. 14 of them were positive for nt551A, one was positive for nt551G, and the other one was positive for nt551T. The results were confirmed by nucleotide sequencing.

CONCLUSION: The mutation specific polymerase chain reaction is a specific and sensitive method for detecting the mutations of HBV genome at nt551.

N/A

N/A

Effect of ribozymes on inhibiting expression of HBV mRNA in HepG2 cells

AIM: To study the activity of ribozymes with multiple cleavage sites and mutated ribozymes on expression of HBV mRNA in HepG2 cells.

METHODS: The triple ribozymes and two cis-ribozymes or two mutated ribozymes were inserted, respectively, into five kinds of eukaryotic plasmids, which were cotransfected into the HepG2 cells with p1.2Ⅱplasmid carring genome of adv-subtype HBV. Cleavage effect of ribozymes on HBeAg and HBcAg were detected by ELISA and laser confocal imaging technique.

RESULTS: The transfected HepG2 cells expressed the expected ribozyme and muta-ribozyme. Intracellular level of HBeAg was surpressed variably with variety of ribozymes. The ribozyme plasmid with tRNA promoter demonstrated the highest inhibitory rate at 81% for suppression HBeAg expression.

CONCLUSION: The ribozymes exert varied inhibitory effect on the expression of HBV in HepG2 cells depending on kinds of eukaryotic expressing plasmids.

N/A

N/A

The analysis of γ-glutamyl transpeptidase gene in different type liver tissues

AIM: To probe the value of γ-glutamyl transpeptidase (GGT) messenger RNA in monitoring canceration of liver cells and for early diagnosis of hepatocellular carcinoma (HCC), by researching the types of GGT messenger RNA (GGTmRNA) in liver tissues and peripheral blood of different hepatopathy.

METHODS: The three types of GGTmRNA (A, B, C) in liver tissues and peripheral blood from the patients with HCC, noncancerous hepatopathy, hepatic benign tumor, secondary carcinoma of liver, and healthy persons were detected by reverse-transcription polymerase chain reaction (RT-PCR).

RESULTS: (1) In normal liver tissues, type A was predominantly found (100.00%), type B was not found, type C was found occasionally (25.00%); (2) The distribution of types of GGTmRNA in liver tissues with acute hepatitis, chronic hepatitis, cirrhosis, alcoholic hepatopathy was similar as in normal liver tissues (P > 0.05), but type B was found in 3 of 18 patients with chronic hepatitis (16.67%), and also in 3 of 11 patients with cirrhosis (27.27%); (3) There was no significant difference of types of GGTmRNA between liver tissues with hepatic benign tumor, secondary carcinoma of liver and normal liver tissues (P > 0.05); (4) Type B was predominant in cancerous tissues with HCC (87.5%), the prevalence of type B in cancerous tissues was significantly higher than that in normal liver tissues (0/12) (P < 0.05), but the prevalence of type A in cancerous tissues (46.88%) was significantly lower than that in normal liver tissues (100.00%) (P < 0.05), and the prevalence of type C (6.25%) in cancerous was the same as that in normal liver tissues (25.00%) (P > 0.05). In noncancerous tissues of livers with HCC, the main types were type A and type B, the prevalence of type A (85.71%, 90.48%) and type C (14.29%, 9.52%) in noncancerous tissues of liver with HCC was similar as that in normal liver tissues (A: 100.00%; C: 25.00%) (P > 0.05), but the prevalence of type B (80.95%, 76.19%) in noncancerous tissues of livers with HCC was significantly higher than that in normal liver tissues (0/12) (P < 0.05); (5) The prevalence of type B (37.5%) in peripheral blood with HCC was higher than that in normal person (0/12) (P < 0.05). In peripheral blood, type B was found in 4 of 11 cases of HCC with serum AFP negative.

CONCLUSION: The shift of types of GGTmRNA from A to B in liver tissues may be closely related to the development of HCC, and the analysis of GGT gene may provide a useful tool for early diagnosis of HCC.

Angiogenesis effect on rat liver after administration of expression vector encoding vascular endothelial growth factor D

AIM

To verify the expressing efficiency and angiogenesis effect after administration of expression vector encoding for vascular endothelial growth factor D in normal and ischemic rat liver.

METHODS

Ten female S-D rats were administrated with liver tissue dot injection of naked PCHO/hVEGF-D, 50 microg/dot, three dots for each. The same amount of physiological saline was used as control in the neighboring lobe. Fourteen S-D rats, using inflow occlusion of left lateral lobe, were divided into two groups, seven rats in each group. One was ischemic plasmid group, which received naked plasmid PCHO/hVEGF-D injection of 150 microg. The other received the equal amount of natural saline injection and designed as control. The expressions of hVEGF-D in mRNA and protein levels were identified by in situ hybridization and immunohistochemistry, respectively. Endothelial cells were labeled by the factor VIII immunohistochemistrically. The average number of peri-sinusoidal capillaries of each group was calculated and compared statistically 8 days after injection.

RESULTS

A large amount of hVEGF-D in mRNA level was found in both normal and ischemic plasmid groups and but none in their corresponding control groups. The protein of hVEGF was also highly expressed in both normal and ischemic plasmid groups than in the controls. The mean number of capillaries under microscopy (X200) of the plasmid group and control was 10.2+/-2.78 vs 7.1+/-2.02 (P<0.05), and those of ischemic plasmid group and ischemic control were 7.43+/-1.72 vs 4.71+/-1.11 with statistical difference (P<0.05).

CONCLUSION

The naked PCHO/hVEGF-D dot injection to normal, ischemic rat liver can produce comparatively high expression of hVEGF in both protein and mRNA levels, and prominently increase the number of new capillaries around hepatic sinuses. Therefore, it could be another ideal choice for the treatment of ischemic liver diseases.

Preparation of human single chain Fv antibody against hepatitis C virus E2 protein and its identification in immunohistochemistry

AIM: To screen human single chain Fv antibody (scFv) against hepatitis C virus E2 antigen and identify its application in immunohistochemistry.

METHODS: The phage antibody library was panned by HCV E2 antigen, which was coated in microtiter plate. After five rounds of biopanning, 56 phage clones were identified specific to HCV E2 antigen. The selected scFv clones were digested by Sfi I/Not I and DNA was sequenced. Then it was subcloned into the vector pCANTAB5E for expression as E-tagged soluble scFv. The liver tissue sections from normal person and patients with chronic hepatitis B and chronic hepatitis C were immunostained with HCV E2 scFv antibody.

RESULTS: The data of scFv-E2 DNA digestion and DNA sequencing showed that the scFv gene is composed of 750 bp. ELISA and immunohistochemistry demonstrated that the human single chain Fv antibody against hepatitis C E2 antigen has a specific binding character with hepatitis virus E2 antigen and paraffin-embedded tissue, but did not react with liver tissues from healthy persons or patients with chronic hepatitis B.

CONCLUSION: We have successfully screened and identified HCV E2 scFv and the scFv could be used in the immunostaining of liver tissue sections from patients with chronic hepatitis C.

Detection of anti-preS1 antibodies for recovery of hepatitis B patients by immunoassay

AIM: To establish a convenient immunoassay method based on recombinant antigen preS1(21-119 aa) to detect anti-preS1 antibodies and evaluate the clinical significance of antibodies in hepatitis B.

METHODS: The expression plasmid pET-28a-preS1 was constructed, and a large quantity of preS1(21-119 aa) fragment of the large HBsAg protein was obtained. The preS1 fragment purified by Ni²⁺-IDA affinity chromatography was used as coated antigen to establish the indirect ELISA based on streptavidin-biotin system for detection of the anti-preS1 antibodies in sera from HBV-infected patients. For follow-up study, serial sera were collected during the clinical course of 21 HBV-infected patients and anti-preS1 antibodies, preS1 antigen, HBV-DNA and other serological HBV markers were analyzed.

RESULTS: preS1(21-119 aa) fragment was highly expressed from the plasmid pET-28a-preS1 in a soluble form in E. coli (30 mg•L⁻¹), and easily purified to high purity over 90% by one step of Ni²⁺-IDA-sepharose 6B affinity chromatography. The purity and antigenicity of the purified preS1(21-119 aa) protein was determined by 150 g•L⁻¹ SDS-PAGE, Western blot and a direct ELISA. Recombinant preS1(21-119 aa) protein was successfully applied in the immunoassay which could sensitively detect the anti-preS1 antibodies in serum specimens of acute or chronic hepatitis B patients. Results showed that more than half of 19 acute hepatitis B patients produced anti-preS1 antibodies during recovery of the disease, however, the response was only found in a few of chronic patients. In the clinical follow-up study of 11 patients with anti-preS1 positive serological profile, HBsAg and HBV-DNA clearance occurred in 6 of 10 acute hepatitis B patients in 5-6 mo, and seroconversion of HBeAg and disappearance of HBV-DNA occurred in 1 chronic patients treated with lavumidine, a antiviral agent.

CONCLUSION: The high-purity preS1(21-119 aa) coated antigen was successfully prepared by gene expression and affinity chromatography. Using this antigen, a conveniently detective system of anti-preS1 antibodies in sera was established. Preliminarily clinical trial the occurrence of anti-preS1 antibodies in acute hepatitis B patients suggests the clearance of HBV from serum in a short-term time, and anti-preS1 positive in chronic patients means health improvement or recovery from the disease.

Extraction and purification of TGFβ and its effect on the induction of apoptosis of hepatocytes

AIM: To extract and purify the transforming growth factor β (TGFβ), and to demonstrate its biological activity in vivo and induction of apoptosis of hepatocytes in vitro.

METHODS: TGFβ was isolated from fresh bovine platelets by acid/ethanol extraction method and purified with ion exchange and gel chromatography. The extracted TGFβ as injected subcutaneously to mice, and its biological activity in vivo was observed 72 hrs post-injection by HE staining. The morphological changes were observed by HE staining and the occurrence of apoptosis was detected by TUNEL method after the human normal hepatic cell line QZG was treated with 8 μg·L^-1TGFβ for 12 hrs in vitro.

RESULTS: The molecular mass 25 ku TGFβ protein was successfully extracted. It was able to induce localized granulation tissue formation in vivo. TGFβ-treated hepatocytes showed obvious apoptotic morphological changes, including the pyknosis and dense-stained nuclei and cytoplasm, the fragmentary, annular or crescent nuclei, and the “bubbling” cytoplasm. Moreover, its apoptotic rate was significantly higher than that of the control group (P < 0.05).

CONCLUSION: Biological active TGFβ protein is extracted and purified successfully from bovine platelets, and it is able to induce the apoptosis of hepatocytes.